Amir Shojaei has built a career in life sciences, focused on the clinical development, registration and commercialization of biopharmaceuticals and biologics in multiple therapeutic areas. As the lead for global development and product strategy in R&D for the Ophthalmics franchise at Shire, Amir leads all aspects of clinical stage assets. Most recently, his team brought Xiidra (lifitegrast) from Phase 3 development through to U.S. FDA filing and eventual approval. Amir has also supported Neuroscience and Gastrointestinal teams at Shire, lending his strategic vision and pragmatic approach to R&D and product strategy teams. Amir has owned and run his own pharmaceutical consulting company, is an author on more than 25 publications in peer-reviewed journals, and is named on several US and international patents.